-
Hepatocellular carcinoma is one of the most common malignancies worldwide, and, for those with advanced disease, treatment responses have been dismal. The current report of a trial of gemcitabine and oxaliplatin offers some hope. Using 2 different schedules of these agents, this study found an approximate 20% objective response rate with stable disease occurring in an additional 50%.
-
Patients with elevated bilirubin treated with irinotecan have an increased risk of toxicity, and a dose reduction is recommended. Patients with elevated AST, creatinine or prior pelvic radiation do not appear to have increased sensitivity to irinotecan, but the data are not adequate to support a specific dosing recommendation.
-
-
Ceiling lifts save backs. That is what Salina (KS) Regional Medical Center concluded, and the investment paid off.
-
When patients dont show up for their appointments, the natural first step for many practices is to penalize the patient. But the problem might not lie with the patient, and if it doesnt, charging the patient a missed-appointment fee or kicking him or her off the patient roster wont improve the clinics no-show and cancellation rate.
-
A predictive modeling program is just the first step in identifying members for a comprehensive disease management program, says Michael Cousins, PhD, manager of health informatics for Health Management Corp. (HMC), based in Richmond, VA.
-
Great-West Healthcares disease management approach won the Denver-based company the award of best disease management program in a national PPO for 2002-2003 from the Disease Management Association of America (DMAA).
-
If youre not calling on the resources of your companys physician medical directors, you may not be maximizing your resources to optimize patient care.
-
-
When it comes to accepting cash payments from providers in exchange for referrals, there is no question: It is expressly forbidden. But what happens with noncash items, such as the seemingly innocuous gifts that show up around the holidays or the New Year. What are the rules?
